1. Home
  2. BMEA vs PUSA Comparison

BMEA vs PUSA Comparison

Compare BMEA & PUSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Biomea Fusion Inc.

BMEA

Biomea Fusion Inc.

SELL

Current Price

$1.37

Market Cap

92.1M

Sector

Health Care

ML Signal

SELL

Logo Aureus Greenway Holdings Inc. Common Stock

PUSA

Aureus Greenway Holdings Inc. Common Stock

N/A

Current Price

$2.53

Market Cap

101.2M

ML Signal

N/A

Company Overview

Basic Information
Metric
BMEA
PUSA
Founded
2017
2023
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Hotels/Resorts
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
92.1M
101.2M
IPO Year
2021
2024

Fundamental Metrics

Financial Performance
Metric
BMEA
PUSA
Price
$1.37
$2.53
Analyst Decision
Buy
Analyst Count
8
0
Target Price
★ $7.00
N/A
AVG Volume (30 Days)
★ 1.7M
902.3K
Earning Date
11-03-2026
11-13-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 69.19
N/A
EPS
N/A
★ N/A
Revenue
N/A
★ $2,964,377.00
Revenue This Year
N/A
$1,620.43
Revenue Next Year
N/A
$140.00
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$0.87
$2.34
52 Week High
$2.24
$4.45

Technical Indicators

Market Signals
Indicator
BMEA
PUSA
Relative Strength Index (RSI) 41.72 28.33
Support Level $1.15 N/A
Resistance Level $1.47 $4.05
Average True Range (ATR) 0.12 0.33
MACD -0.03 -0.13
Stochastic Oscillator 18.31 11.78

Price Performance

Historical Comparison
BMEA
PUSA

About BMEA Biomea Fusion Inc.

Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.

About PUSA Aureus Greenway Holdings Inc. Common Stock

Aureus Greenway Holdings Inc own and operate two public golf country clubs in Florida. The golf country clubs include two golf-courses with over 13,000 yards of combined fairways, clubhouses boasting food and beverage options, aquatic golf ranges, and pro shops to assist any level of golfer and also host local golf leagues, golf-tournaments, and private events. Its golf country clubs is organized into four principal business segments: (i) golf recreation, retail golf products, and equipment and facilities rental, (ii) membership dues, (iii) food and beverage services. and (iv) ancillary services and amenities. All assets of the Company are located in Florida and all revenue is generated from Florida.

Share on Social Networks: